Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (Patentes Nacionales, Patentes Europeas, Informes Tecnológicos de Patentes y Búsquedas Retrospectivas) está cerrado desde el pasado 19 de junio. Se informará más adelante sobre su reapertura.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
129
resultados
Última actualización
07/07/2025 [14:45:00]
Resultados 100 a 125 de 129
Resumen de: CN119391523A
The invention discloses an in-vitro bionic intestinal barrier injury micro-physiological system. The device comprises a stomach digestion simulation system, a small intestine digestion simulation system, a small intestine interaction simulation system, a large intestine glycolysis simulation system and a large intestine interaction simulation system. According to the invention, the physicochemical environment for digestion of patients with inflammatory bowel diseases (IBD) is simulated by adjusting parameters such as pH, and the physiological system of the patients with IBD is simulated through human-derived organs and microorganisms. The in-vitro substitution model not only simulates gastrointestinal digestion, absorption and glycolysis processes of a patient with intestinal barrier injury in vitro, but also simulates interaction between food and metabolites thereof and intestinal tracts through introduction of organoids. The model can be used for exploring the metabolic process or toxic effect of food in the body of a patient suffering from intestinal barrier injury, evaluating the bioaccessibility, metabolic fate, interaction with microorganisms and influence on intestinal physiology of the food, and realizing precise risk assessment.
Resumen de: CN119395122A
本发明公开了一种用于炎症性肠病诊断的粪便生物标志物及其应用，该粪便生物标志物为肾上腺酸。本发明通过实验首次发现了肾上腺酸在IBD患者粪便样本中呈现上调，经检测发现肾上腺酸在IBD患者粪便标本中表达上调；进一步通过ROC曲线分析肾上腺酸相比于其他钙粘蛋白等炎症活动指标而言，具有较好的诊断敏感度和特异性。本发明为IBD的临床诊断提供了新的诊断标志物，以肾上腺酸作为IBD诊断的粪便生物标志物，用于炎症性肠病的诊断，具有检测精确度高、特异性和灵敏性高、方便快捷以及安全无创等优点，对判断IBD的活动状态、调整IBD患者的诊疗及管理等均具有重要意义。
Resumen de: WO2025024629A2
Provided herein are gene replacement approaches to restore HOXA11AS in the colon for patients with IBD, e.g., UC. Further, since HOXA11os levels inversely correlate with disease severity this lncRNA can also be used as a sensitive colon specific disease relevant biomarker.
Resumen de: US2025034613A1
Provided herein are engineered bacterial biosensors and methods of use thereof for detection of gastrointestinal disease, including inflammatory bowel disease.
Resumen de: CN119367543A
The invention discloses an application of an Ander-1 expression promoter in preparation of a medicine for preventing and treating ulcerative colitis. The invention discovers that the expression level of the And-1 is obviously reduced in the ulcerative colitis, the ulcerative colitis can be obviously aggravated by knocking out or silencing the And-1, and the ulcerative colitis can be obviously improved by overexpressing the And-1. Accordingly, technicians in the field can determine that the And-1 expression promoter can be used for preparing the medicine for preventing and treating the ulcerative colitis, and the And-1 gene or protein can be used as a medicine action target for screening and finding the medicine for preventing and treating the ulcerative colitis and a marker for diagnosis, treatment or prognosis of the ulcerative colitis; wherein the And-1 expression promoter is a substance for promoting And-1 expression, can be a nucleotide sequence for promoting And-1 expression or a carrier containing the nucleotide sequence, and can also be a small molecule compound, polypeptide or polysaccharide for promoting And-1 expression.
Resumen de: CN119360942A
The invention provides an ulcerative colitis intestinal microbial marker, application thereof and an ulcerative colitis detection model, and belongs to the technical field of biology and biological medicine. By analyzing the composition of the intestinal microbe markers of the ulcerative colitis patient and monitoring the change of the intestinal microbe markers of the patient, the method can guide the adjustment of the intestinal microecology of the ulcerative colitis patient, makes a personalized treatment scheme for each UC patient, recovers the normal flora of the intestinal tract of the ulcerative colitis patient, and improves the treatment effect of the ulcerative colitis. The treatment effect is improved. The ulcerative colitis detection model can more accurately identify the intestinal flora difference between ulcerative colitis patients and healthy people, the ROC curve of the ulcerative colitis detection model is close to the upper left corner, the ulcerative colitis detection model has a high true positive rate under each threshold value, the AUC value reaches 0.8106, and the ulcerative colitis detection model can be used for detecting the ulcerative colitis. The ulcerative colitis detection model has good performance when distinguishing positive and negative samples.
Resumen de: CN119345337A
The invention discloses a deubiquitination enzyme drug. The deubiquitination enzyme drug comprises a deubiquitination enzyme, an antioxidant nano-enzyme and a carrier for loading the deubiquitination enzyme and the antioxidant nano-enzyme. The deubiquitination enzyme medicine contains the deubiquitination enzyme and the antioxidant nano-enzyme, and the antioxidant nano-enzyme removes redundant ROS at the colon lesion, so that the biological activity of the deubiquitination enzyme can still be maintained in an inflammation microenvironment, and inflammation of the lesion is relieved. The invention further discloses a preparation method of the deubiquitination enzyme medicine. The preparation method is simple in process and short in time consumption. The invention also discloses application of the deubiquitinating enzyme medicine in preparation of medicines for treating and/or diagnosing inflammatory bowel diseases. The deubiquitinating enzyme medicine can activate an inertial cavitation mechanism through O2 microbubbles in an oxidative stress microenvironment of the inflammatory bowel disease, so that a photoacoustic signal is specifically generated, and accurate diagnosis of pathological changes of the inflammatory bowel disease and accurate treatment guided by photoacoustic imaging are realized.
Resumen de: CN119331783A
The invention provides a Villonella enteritidis strain and an application of the Villonella enteritidis strain. The preservation number of the Villonella enteritidis strain is GDMCC No: 65234. The invention also provides a preparation containing the Wehonor enteritidis, a culture method and application of the Wehonor enteritidis as a labeled microorganism or a target spot in preparation of drugs for screening diseases caused by the Wehonor enteritidis. According to the present invention, the virulence gene and the pathogenicity of the Wehonor enteritidis are analyzed, such that the Wehonor enteritidis has the potential pathogenicity for aggravating the inflammatory bowel disease, and the strain provides specificity in the aspects of biological characteristics, pathogenicity and the like compared with the Wehonor micrococcus, such that the cognition of the Wehonor micrococcus in the intestinal tract is new improved, and the Wehonor micrococcus enteritidis can be used for the treatment of the inflammatory bowel disease. Moreover, a new view angle and a new direction are provided for research on the effect of the Wehonor coccus in the intestinal diseases such as IBD (Infectious Bursal Disease).
Resumen de: US2025020667A1
Embodiments of the disclosure include systems, methods, and compositions for detection of imminent onset of a symptom of a gut inflammation medical condition. The disclosure also concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual with IBD.
Resumen de: US2025020660A1
The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
Resumen de: CN119307602A
The invention discloses application of an EphB3 gene as a biomarker in preparation of a Crohn disease detection product. According to the present invention, the expression of the EphB3 gene in the Crohn disease patient is significantly up-regulated, such that the EphB3 gene can be adopted as the Crohn disease-related biomarker, can specifically detect the Crohn disease infection, and has extremely high accuracy. Meanwhile, according to the application of a reagent for detecting EphB3 receptor expression in preparing a reagent for identifying and diagnosing the Crohn disease, the expression quantity of EphB3 in the intestinal mucosa of a patient suffering from the Crohn disease is remarkably increased compared with the expression quantity of EphB3 in the intestinal mucosa of a patient suffering from enterophthisis and a patient suffering from primary intestinal lymphoma, and the difference has statistical significance (Plt; therefore, the detection of the expression of the EphB3 can be used for differential diagnosis of Crohn's disease, intestinal tuberculosis and primary intestinal lymphoma, and has extremely high specificity and accuracy.
Resumen de: CN119291196A
The invention relates to the technical field of medicinal chemistry and pharmacotherapeutics, in particular to a technology and a method for confirming toxic targets of evodiamine (EVO) and accurately evaluating hepatotoxicity of evodiamine. The method comprises the following steps: determining that EVO can be directly combined through biotin labeling, pulldown, mass spectrum combination, small molecule transfection and the like, and up-regulating liver zo-1 protein to cause liver injury, while up-regulating the intestinal tract target is a key mechanism for treating the inflammatory bowel disease by EVO. By comparing the protein levels in the liver-intestine axes of animals in different states, the fact that the down-regulation of the ZO-1 protein level in the liver-intestine axis under the inflammatory bowel disease state can partially antagonize the EVO to the up-regulation of the liver ZO-1 is found, so that the liver toxicity is reduced, and only the therapeutic activity of the EVO is retained. The discovery provides an accurate target spot for understanding an EVO toxicity mechanism, and is beneficial to realizing accurate regulation and control in drug research and development and toxicity prevention in the future; meanwhile, the drug effects and toxic mechanisms of EVO in organisms in different states are compared from the aspect of ZO-1 protein expression in the liver-intestine axis, and direct evidence is provided for the theory of combating poison with poison in to
Resumen de: CN119291201A
The invention provides a detection kit for the expression quantity of HGFAC protein in body fluid, a construction method of an IBD detection model and application of the method in IBD auxiliary diagnosis, treatment effect monitoring and prognosis outcome prediction, belongs to the field of biological medicine, and solves the problem of how to carry out IBD auxiliary diagnosis, treatment effect monitoring and prognosis outcome prediction through body fluid biomarkers. The method comprises the following steps: inputting body fluid data obtained by the HGFAC protein expression quantity in a body fluid sample detected by the detection kit into a Logistic regression model to obtain an IBD auxiliary diagnosis model; inputting target body fluid data after conventional treatment into a Logistic regression model to obtain an IBD treatment effect monitoring and prognosis outcome prediction model; and selecting an optimal random seed number according to an AUC value of an ROC curve established by the model to obtain an optimal model, and performing k-folding cross validation on the optimal model to obtain an optimal model. According to the invention, IBD auxiliary diagnosis, treatment effect monitoring and prognosis outcome prediction are carried out through the optimal model based on the body fluid biomarkers, and clinical requirements are met.
Resumen de: WO2025008439A1
The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and/or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.
Resumen de: JP2025003474A
To provide apparatuses for assessment of microvascular dysfunction.SOLUTION: The invention provides methods and devices for assessment of microvascular dysfunction such as microvascular obstruction (MVO) and other dysfunctional diseases of the microvasculature of many organs, including the heart. The present subject matter provides novel devices and methods to normally diagnose, restore patency, open and preserve a flow, and limit reperfusion injury in organs and cases with microvascular dysfunction. The present subject matter provides apparatuses and methods to detect, measure and treat microvascular dysfunction in real time during scenarios such as invasive angiographic/therapeutic procedures. Such procedures include therapy for organ systems including the heart (acute myocardial infarction-primary percutaneous coronary intervention (PPCI)), brain stroke (CVA), bowel ischemia/infarction, pulmonary emboli/infarction, critical limb ischemia/infarction, renal ischemia/infarction, and others.SELECTED DRAWING: Figure 1
Resumen de: EP4487864A1
The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and/or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.
Resumen de: CN119242783A
The invention discloses an application of PNO1 in construction of an ulcerative colitis animal model. PNO1 is applied to at least one of the following items: (1) preparing a product for diagnosing ulcerative colitis; (2) screening candidate drugs for preventing and/or treating ulcerative colitis as targets; and (3) constructing the ulcerative colitis animal model. The invention firstly finds that the PNO1 gene is positively correlated with the ulcerative colitis and can be used as a marker for diagnosing the ulcerative colitis, so that the ulcerative colitis is more accurately and quickly diagnosed, and a new therapeutic target and a new therapeutic approach are provided for treating colon cancer. The invention further constructs an ulcerative colitis animal model which can be better used for pathogenic mechanism and treatment research of ulcerative colitis and screening of colitis candidate drugs.
Resumen de: CN119235918A
The invention relates to the technical field of biomedicine, in particular to a preparation process of gold juice and application of the gold juice in modern disease treatment. The preparation process of the gold juice comprises the following steps: collecting and storing excrement; diluting and filtering; sealing in a jar; long-term curing; and digging the jar to take liquid. The invention discloses an application of Jinjiang in modern disease treatment. The application comprises the following disease treatment fields: the Jinjiang is used for treating septicopyemia; the compound is used for treating intestinal related diseases, including inflammatory bowel disease and irritable bowel syndrome; the traditional Chinese medicine composition is used for treating immune system diseases, including rheumatic arthritis and systemic lupus erythematosus; the pharmaceutical composition is used for treating metabolic syndromes including obesity, diabetes and hypertension. The preparation method disclosed by the invention achieves remarkable achievements in the aspects of a preparation process, modern medical application, pharmacological research, material component analysis, curative effect verification and the like of the traditional Chinese medicine Jinjin juice, and makes positive contributions to inheritance and development of the traditional Chinese medicine Jinjin juice.
Resumen de: WO2025006940A2
Aspects of the disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBDs"), such as ulcerative colitis ("UC") and/or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an exterior surface of the core. In some cases, the protease inhibitor is a gliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and/or small intestine of a subject to whom the pharmaceutical dosage form is administered. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., a bacterial protease) to the large intestine (e.g., colon) and/or small intestine of a subject.
Resumen de: WO2025003436A1
The present application provides an ultrasensitive colorimetric assay as well as an early biomarker for patient monitoring and medical treatment of patients suffering from a possible mitochondrial dysfunction, inflammatory bowel disease, particularly Crohn's disease. The ultrasensitive colorimetric assay measures the level of L-citrulline in a plasma or serum sample; and when the level of L-citrulline in plasma or serum decreases or falls even below 30 µmol L-citrulline, this indicates a mitochondrial cell disorder caused by a relapse or an increase in intestinal inflammation due to a flare of Crohn's disease. A method of detecting and treating the mitochondrial dysfunction is also provided.
Resumen de: CN119220678A
The invention relates to the technical field of biology, in particular to a kit related to colitis and proctitis malignant transformation, which comprises an intelligent system and a top cover, a semiconductor chilling plate is arranged at the bottom of the top cover, and a cooling fin is arranged at the top of the top cover; one side of the top cover is rotationally connected with a box body; a plurality of partition plates are fixedly connected into the box body and divide the interior of the box body into a plurality of containing cavities, and fixing assemblies are arranged on the side walls of the containing cavities. The miRNA marker related to the malignant transformation of colitis and proctitis comprises a miRNA marker body, and the miRNA marker body is one or more of miR-138-5p, miR-145-5p, miR-146a-5p, miR-150-5p, miR-146a, miR-27a, miR-29a, miR-20a and miR-21. The miRNA marker can be used for detecting the malignant transformation of colitis and proctitis. A detection agent is fixed through an elastic stretching plate and a magnet, so that the possibility that the detection agent is damaged is reduced; the interior of the kit is cooled through a semiconductor chilling plate, so that a detection agent and a detection plate can be stored for a long time; high-throughput detection of the miRNA marker is realized through the detection plate, and the detection efficiency is improved.
Resumen de: CN119223942A
本发明公开了一种磁性水凝胶包裹细菌生物传感器平台与应用，属于合成生物学及临床诊断领域。该水凝胶递送回收体系包括水凝胶包裹的全细胞生物传感器和磁性微粒，其中，所述水凝胶由海藻酸钠和氯化钙构建，所述生物传感器为感应血红素的细菌。更具体地，本发明是使用海藻酸钠水凝胶封装工程细菌YES601和磁性Fe3O4微粒形成磁性水凝胶微球，作为生物传感器递送至肠道可以感应血红素而发光，再通过磁性吸附的方式从粪便中高效回收完整微球进行检测，提高了全细胞生物传感器检测肠道出血效率以及安全性。本发明提供的水凝胶递送回收体系整体设计优化策略可以提高诊断效率和实际应用价值。
Resumen de: US2024425923A1
Described herein are systems and methods for stratifying intestinal mononuclear phagocytes (MNP) expression profiles in subjects with an inflammatory bowel disease (IBD). Further provided herein are systems and methods for determining or characterizing a Crohn's Disease (CD) subtype status in a subject having CD, selecting a treatment for a subject, or treating a subject.
Resumen de: FI20225151A1
The present invention is related to a method for determining or confirming chronic inflammatory intestinal disease or a risk thereof in a subject. The method comprises detecting the presence of keratin 7 (K7) mRNA or protein in a biological sample obtained from a subject.
Nº publicación: CN119183380A 24/12/2024
Solicitante:
NATIONAL UNIV CORPORATION THE UNIV OF TOKYO
\u56FD\u7ACB\u5927\u5B66\u6CD5\u4EBA\u4E1C\u4EAC\u5927\u5B66
Resumen de: CN119183380A
The present disclosure relates to: a method for treating IBD using digestive tract content or excreta modified with an IgA antibody, a composition, and a method for producing the same; a method for obtaining an IgA antibody that makes the flora in the digestive tract of an IBD patient sound; methods, compositions, and methods of making the same for modifying the contents or excreta of the digestive tract of an IBD patient using an IgA antibody; a method for testing a patient treated with an IBD therapeutic agent containing digestive tract contents or excreta using a diagnostic agent containing an IgA antibody; a composition; and a method for producing the composition.
BOPI
Sede Electrónica
